9YGS
Crystal structure of GMPPNP bound KRAS-Y71H in complex with RBD domain of CRAF(RAF1)
Summary for 9YGS
| Entry DOI | 10.2210/pdb9ygs/pdb |
| Descriptor | Isoform 2B of GTPase KRas, RAF proto-oncogene serine/threonine-protein kinase, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, ... (5 entities in total) |
| Functional Keywords | gtpase kinase cell signaling complex, oncoprotein |
| Biological source | Homo sapiens (human) More |
| Total number of polymer chains | 2 |
| Total formula weight | 29095.08 |
| Authors | |
| Primary citation | Sang, B.,Ye, L.F.,Fu, Z.,Pourfarjam, Y.,Cuevas-Navarro, A.,Fan, S.,Hu, F.,Washington, A.,Rodriguez, D.J.,Vides, A.,Kar, S.,Ahler, E.,Lin, K.K.,Hegde, A.,Smith, J.A.M.,Wolpin, B.M.,Punekar, S.R.,Spira, A.I.,Garrido-Laguna, I.,Hong, D.S.,Dar, A.C.,Yaeger, R.,Arbour, K.C.,Lito, P. Disrupted molecular glue complex drives RAS inhibitor resistance. Cell, 2026 Cited by PubMed Abstract: Tri-complex inhibitors (TCIs) are molecular glues that bind the active, guanosine triphosphate (GTP)-bound state of RAS and recruit cyclophilin A (CYPA) to form a synthetic complex that blocks oncogenic signaling. Although these agents have shown clinical activity in RAS mutant cancers, resistance mechanisms remain poorly defined. Here, we analyzed paired baseline and end-of-treatment samples from 40 patients treated with the RAS inhibitor daraxonrasib and identified recurrent alterations in 18 cases. Structural and functional analyses revealed that acquired mutations confer resistance by disrupting interactions essential for daraxonrasib binding to RAS, including RAS Y64 mutations, or by enhancing the RAS-RAF interaction, thereby favoring native RAS-RAF signaling, including RAS Y71 or kinase-dead/hypoactive BRAF mutations. We then identified a TCI that targets RAS Y64 mutants and combination therapies to target resistance driven by kinase-dead BRAF. These findings uncover convergent resistance mechanisms that undermine the molecular glue function and offer a mechanistic blueprint for enhancing therapeutic efficacy in RAS-driven malignancies. PubMed: 42092352DOI: 10.1016/j.cell.2026.03.031 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.68 Å) |
Structure validation
Download full validation report
